PTC Therapeutics shares are trading lower after the CHMP issued a negative opinion on Translarna following the European Commission's request for review.
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics shares are trading lower after the CHMP issued a negative opinion on Translarna following the European Commission's request for review.
June 28, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics shares are experiencing a decline due to a negative opinion from the CHMP on their drug Translarna, following a review request by the European Commission.
The negative opinion from the CHMP on Translarna is a significant regulatory setback for PTC Therapeutics, likely leading to a short-term decline in stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100